|
Includes Clinical Data for XL147, XL765 and XL139
SOUTH SAN FRANCISCO, Calif.(BUSINESS WIRE)
Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts
related to the company's development candidates have been accepted for
presentation at the 2009 AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics, which is being held November
15-19 in Boston. Interim data from ongoing phase 1 clinical trials of
XL147 and XL765 will be reported in four poster presentations. Exelixis
is co-developing XL147 and XL765 in collaboration with sanofi-aventis.
Clinical data for an ongoing phase 1 trial of XL139, which is being
co-developed with Bristol-Myers Squibb, will also be reported. Other
poster presentations will cover a variety of preclinical data and
preclinical and clinical biomarker data for six compounds.
Clinical Data Presentations
-
A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2
inhibitor, XL765 (SAR245409), in combination with erlotinib in
patients (pts) with advanced solid tumors will be presented on Monday,
November 16, 2009, during the 12:30 pm 2:30 pm poster session
(Abstract #A254)
-
A first-in-human, phase 1 study of an oral hedgehog pathway
antagonist, BMS-833923 (XL139), in subjects with advanced or
metastatic solid tumors will be presented on Monday, November 16,
2009, during the 12:30 pm 2:30 pm poster session (Abstract #A55)
-
A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor
XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin
(C) in patients with advanced solid tumors will be presented on
Tuesday, November 17, 2009, during the 12:30 pm 2:30 pm poster
session (Abstract #B247)
-
A phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a
novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide
(TMZ) in patients (pts) with malignant glioma will be presented on
Tuesday, November 17, 2009, during the 12:30 pm 2:30 pm poster
session (Abstract #B265)
-
A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor
XL147 (SAR245408) in combination with erlotinib in patients with
advanced solid tumors will be presented on Wednesday, November 18,
2009, during the 12:30 pm 2:30 pm poster session (Abstract #C197)
Biomarker Data Presentations
-
Pharmacodynamic and correlative biomarker analyses in clinical trials
of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET will be
presented on Tuesday, November 17, 2009, during the 12:30 pm 2:30 pm
poster session (Abstract #B269)
-
Characterization of the target profile of XL228, a multi-targeted
protein kinase inhibitor in phase 1 clinical development will be
presented on Wednesday, November 18, 2009, during the 12:30 pm 2:30
pm poster session (Abstract #C192)
To access the clinical data posters mentioned in this press release,
please visit www.exelixis.com.
Please note that the clinical data posters will be available at time of
presentation.
Preclinical Data Presentations
-
Reduction of tumor invasiveness and metastasis and prolongation of
survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by
XL184 will be presented on Monday, November 16, 2009, during the 12:30
pm 2:30 pm poster session (Abstract #A13)
-
Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH)
pathway inhibitor in early clinical development will be presented on
Tuesday, November 17, 2009, during the 12:30 pm 2:30 pm poster
session (Abstract #B192)
-
XL388: A novel, selective, orally bioavailable mTORC1 and mTORC2
inhibitor that demonstrates pharmacodynamic and antitumor activity in
multiple human cancer xenograft models will be presented on Tuesday,
November 17, 2009, during the 12:30 pm 2:30 pm poster session
(Abstract #B146)
-
Discovery and characterization of selective PI3K and PI3K/mTOR-dual
inhibitors for targeting PI3K-activated tumors will be presented on
Wednesday, November 18, 2009, during the 12:30 pm 2:30 pm poster
session (Abstract #C59)
-
Targeting tumor cell glycolysis: Discovery and characterization of
small molecule inhibitors of IPFK2 (Inducible
6-Phosphofructo-2-Kinase) will be presented on Wednesday, November 18,
2009, during the 12:30 pm 2:30 pm poster session (Abstract #C70)
-
Assessment of Gli1 expression during skin regeneration in mouse models
and normal healthy volunteers will be presented on Wednesday, November
18, 2009, during the 12:30 pm 2:30 pm poster session (Abstract #C18)
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech,
Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For
more information, please visit the company's web site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice
President, Corporate Communications & Investor Relations
cbutler@exelixis.com
Source: Exelixis, Inc.
|
